Close
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Jun 12 2024 12:00
    76,606.57 +149.98 ( +0.20%)
  • NIFTY Jun 12 2024 12:00
    23,322.95 +58.10 ( +0.25%)
  • SENSEX Jun 12 2024 12:00
    76,606.57 +149.98 ( +0.20%)
  • NIFTY Jun 12 2024 12:00
    23,322.95 +58.10 ( +0.25%)
  • Nasdaq Jun 12 2024 04:30
    17,343.55 +151.02 ( +0.88%)
  • DJIA Jun 12 2024 04:30
    38,747.42 -120.62 (-0.31%)
  • S&P 500 Jun 12 2024 04:30
    5,375.32 +14.53 ( +0.27%)
  • Hang Seng Jun 12 2024 02:10
    17,937.84 -238.50 (-1.31%)
  • Crude Oil Jun 12 2024 11:29
    6,571.00 +45.00 ( +0.69%)
  • Gold Jun 12 2024 11:29
    71,905.00 -65.00 (-0.09%)
  • Silver Jun 12 2024 11:29
    90,400.00 +1,737.00 ( +1.96%)
  • Copper Jun 12 2024 11:29
    867.45 +0.25 ( +0.03%)
  • Pound / Rupee Dec 23 2016 22:30
    106.22 +0.02 ( +0.02%)
  • Dollar / Rupee Dec 23 2016 22:30
    83.51 0.00 ( +0.01%)
  • Euro / Rupee Dec 23 2016 22:30
    89.83 -0.34 (-0.37%)
  • Yen / Rupee Dec 23 2016 22:30
    0.53 0.00 (-0.12%)

Apollo Hospitals Enterprise Ltd

BSE Code : 508869 | NSE Symbol : APOLLOHOSP | ISIN:INE437A01024| SECTOR : Healthcare |

NSE BSE
 
SMC up arrow

6,168.60

60.65 (0.99%) Volume 321285

12-Jun-2024 EOD

Prev. Close

6,107.95

Open Price

6,117.30

Bid Price (QTY)

6,168.60(80)

Offer Price (QTY)

0.00(0)

 

Today’s High/Low 6,188.85 - 6,075.00

52 wk High/Low 6,874.45 - 4,726.00

Key Stats

MARKET CAP (RS CR) 88714.41
P/E 87.79
BOOK VALUE (RS) 536.2806081
DIV (%) 300
MARKET LOT 1
EPS (TTM) 70.28
PRICE/BOOK 11.5050775784335
DIV YIELD.(%) 0.1
FACE VALUE (RS) 5
DELIVERABLES (%) 34.3

F&O Quote

6,177

63 (1%)
Open Price 6,110 Average Price 6,151 Open interest 2,136,250
High Price 6,196 No. Of Contracts Traded 546,375 Open Interest Change -19,125
Low Price 6,084 Turnover (`. In Lakhs) 3,360,561,394 Open Interest Change(%) -1%
Prev. Close 6,115 Market Lot 125 Option Chain | Detailed View >>
4

News & Announcements

07-Jun-2024

Apollo Hospitals Enterprise Ltd - Apollo Hospitals Enterprise Limited - Analysts/Institutional Investor Meet/Con. Call Updates

07-Jun-2024

Apollo Hospitals Enterprise Ltd - Apollo Hospitals Enterprise Limited - Analysts/Institutional Investor Meet/Con. Call Updates

05-Jun-2024

Apollo Hospitals Enterprise Ltd - Apollo Hospitals Enterprise Limited - Loss of Share Certificates

05-Jun-2024

Apollo Hospitals Enterprise Ltd - Apollo Hospitals Enterprise Limited - Loss of Share Certificates

31-May-2024

Board of Apollo Hospitals Enterprise recommends final dividend

03-May-2024

Apollo Hospitals Enterprise to table results

02-Apr-2024

Apollo Hospitals Enterprise announces cessation of director

08-Feb-2024

Board of Apollo Hospitals Enterprise recommends interim dividend

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
3B Blackbio DX Ltd 532067
Aashka Hospitals Ltd 543346
Aatmaj Healthcare Ltd 78782 AATMAJ
Adeshwar Meditex Ltd 543309
Advanced Micronic Devices Ltd 517552
Amkay Products Ltd 544169
Artemis Global Life Sciences Ltd((Merged) 540616 AGLSL
Artemis Medicare Services Ltd 542919 ARTEMISMED
Asarfi Hospital Ltd 543943
Aspira Pathlab & Diagnostics Ltd 540788
Aster DM Healthcare Ltd 540975 ASTERDM
Bandaram Pharma Packtech Ltd 524602
Casil Health Products Ltd(merged) 523254
CDR Health Care Ltd 523353
Centenial Surgical Suture Ltd 531380
Chennai Meenakshi Multispeciality Hospital Ltd 523489
Cure Spects Laser Ltd 531356
Datt Mediproducts Ltd 532171 DATTMEDI
Deccan Hospital Corporation Ltd (Merged) 523258
Dhanvantri Jeevan Rekha Ltd 531043
Digiflex India Ltd 526111
Disposable Medi - Aids Ltd 523540
Dolphin Medical Services Ltd 526504
Dr Agarwals Eye Hospital Ltd 526783
Dr Lal Pathlabs Ltd 539524 LALPATHLAB
Dr Lalchandani Labs Ltd 541299
Emaai Pharma Ltd 524756
Family Care Hospitals Ltd 516110
Fidelity Industries Ltd (Wound-up) 526425
Fortis Healthcare Ltd 532843 FORTIS
Fortis Malar Hospitals Ltd 523696
Gian Lifecare Ltd 542918
Gil Hospitals Ltd (Wound-up) 526063
Global Health Ltd 543654 MEDANTA
Global Longlife Hospital and Research Ltd 543520
GPT Healthcare Ltd 544131 GPTHEALTH
Healthcare Global Enterprises Ltd 539787 HCG
Hemant Surgical Industries Ltd 543916
Indraprastha Medical Corporation Ltd 532150 INDRAMEDCO
Iswar Medical Services Ltd 507480 ISWARMEDIC
Jupiter Life Line Hospitals Ltd 543980 JLHL
Kemwell International Ltd 530827
Keshlata Cancer Hospital Ltd 40450
Kids Medical Systems Ltd 540812
KK Shah Hospitals Ltd 544013
KMC Speciality Hospitals (India) Ltd 524520
KMS Medisurgi Ltd 540468
Kovai Medical Center & Hospital Ltd 523323 KOVAI
Krishna Institute of Medical Sciences Ltd 543308 KIMS
Krsnaa Diagnostics Ltd 543328 KRSNAA
La Medical Devices Ltd (Wound-up) 524772
Lifeline Injects Ltd 523379
Lokmanya Industries Ltd 526421
Looks Health Services Ltd 534422
Lotus Eye Hospital & Institute Ltd 532998 LOTUSEYE
Maestros Electronics & Telecommun. Systems Ltd 538401
Maestros Mediline Systems Ltd 501209
Maitreya Medicare Ltd 91877 MAITREYA
Max Healthcare Institute Ltd 543220 MAXHEALTH
Medinova Diagnostic Services Ltd 526301
Metropolis Healthcare Ltd 542650 METROPOLIS
Mohini Health & Hygiene Ltd 532585 MHHL
Monozyme India Ltd 522199
N G Industries Ltd 530897
Narayana Hrudayalaya Ltd 539551 NH
New World Medical (India) Ltd 524496
Nidan Laboratories & Healthcare Ltd 535411 NIDAN
Noida Medicare Centre Ltd 523670
Nova Surgikos Ltd 524762
One Global Service Provider Ltd 514330
Opto Circuits (India) Ltd 532391 OPTOCIRCUI
Poly Medicure Ltd 531768 POLYMED
Pramila Kidney Hospitals Ltd 40265
Prevest Denpro Ltd 543363
Rainbow Childrens Medicare Ltd 543524 RAINBOW
Regency Hospital Ltd 526403
Safire Global Medicare Ltd 524418 CDRMEDICAL
Sangam Health Care Products Ltd 531625
Sangani Hospitals Ltd 79231 SANGANI
Secunderabad Healthcare Ltd 524540
Shalby Ltd 540797 SHALBY
Sharma East India Hosp and Medical Research Ltd 524548
Shree Pacetronix Ltd 527005
Siemens Healthcare Diagnostics Ltd(merged) 506559
Soni Medicare Ltd 539378
Sterling (Gujarat) Hospitals Ltd 531741
Surgiplast Ltd 523077
Surlux Diagnostic Ltd 507854
Surlux Health Centres Ltd 523265
Surlux Mediquip Ltd 523515
Tamilnad Hospital Ltd 523443
Tejnaksh Healthcare Ltd 539428
Thyrocare Technologies Ltd 539871 THYROCARE
Transmedica (India) Ltd 526461
Twenty First Century Medicare Ltd 40212
Unihealth Consultancy Ltd 91654 UNIHEALTH
United Diagnostic International Ltd 523485
Vijaya Diagnostic Centre Ltd 543350 VIJAYA
Yatharth Hospital & Trauma Care Services Ltd 543950 YATHARTH

Share Holding

Category No. of shares Percentage
Total Foreign 66656345 46.36
Total Institutions 28109314 19.55
Total Govt Holding 323708 0.23
Total Non Promoter Corporate Holding 407765 0.28
Total Promoters 42177612 29.33
Total Public & others 6109913 4.25
Total 143784657 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Apollo Hospitals Enterprise Ltd

Apollo Hospitals Enterprise Limited (AHEL) is a leading private sector healthcare provider in Asia. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics. AHEL's Hospitals are situated in Chennai, Hyderabad, Delhi, Ahmedabad, Pune, Chenganur, Coimbatore, Jaipur, Madurai, Anantpur, Nellore, Kurnool, Bhopal, Ranchi, Bilaspur and Bacheli. Apollo Hospitals Enterprise Limited was incorporated as a Public Limited Company on December 5, 1979, a comprehensive 250-bed hospital with an emphasis on speciality and super specialties in over fifty departments at Chennai. Dr. Prathap C Reddy promoted it. 46 beds were added in the year 1985. It is the first group of hospitals that pioneered the concept of corporate healthcare delivery in India. The Apollo Health Association (AHA) was inaugurated in April of the year 1986, based on credit card system. As per this scheme, the Apollo health insurance policyholders get Medicare offered by Apollo and 76 accredited hospitals in selected cities. The hospital was equipped with Magnetic Resonance Imaging (MRI) during the year 1989, also with SOMATOMCR whole body computed Tomography scanner, Dideoendoscopy and Mammography, breast-scanning equipment for the detection of occult carcinoma. During the same year 1989, AHEL group had finalised a joint venture project with the I.R.T.C. of Eye Micro Surgery, USSR to launch the Apollo Fyodorov Eye Research Institute. Apart from the hospital activities, The Apollo School of nursing was commissioned in August of the year1991, which offers a 3-year diploma programme followed by internship in the hospital. During the year 1992, 16 intensive care beds and 26 additional patient beds together with balancing equipment were added in various disciplines. Also a 24-hour ambulance service with wireless facility was to be launched. Apollo cancer hospital was commissioned with 150-beds for cancer treatment and research centre in Chennai during the period of 1993. Further, AHEL had introduced state-of-the-art Bone Marrow transplant facility in Phase II expansion of cancer project. A third theater was added for cardio thoracic surgery in the year of 1994. As at 19th February of the year 1995, another one wing was added, Cancer hospital in Hyderabad was inaugurated. In the same year 1995, AHEL had joined hands with the WHO with its mission to eradicate Tuberculosis in India. With takeover of Orient Hospital, Madurai and Pinakini Hospital, Nellore, the Company had added 300 more beds in the year 1996 and the Apollo College of Nursing at Keezhkattalai was inaugurated on 21st October of the same year. AHEL had signed a memorandum of understanding with Jardine of UK for successful adaptation of the health maintenance organisations (HMO) in the year 1997, a concept for the first time in India. A year after, in 1998, also signed a memorandum of understanding with the Sri Lankan Government to build a super-speciality hospital in Colombo. It was the first time the speciality hospital group ventured abroad with investments. AHEL had opened a unit for the Kidney disorders; it was inaugurated in April of the year 1998 with the expansion in this facility for better and newer techniques in treatment. In 1999, Apollo had launched its first poison information centre in the south of the India. Indian Oil Corporation Ltd (IOCL) and AHEL had signed a memorandum of understanding (MoU) in the year 2000 for setting up pharmaceutical general stores at the convenience stores of Indian Oil petrol stations. Apollo and Royal College of General Practioners made a tie-up in the period of 2000 to launch three programmes for revalidating and updating the knowledge of primary healthcare physicians in India. The company also inked an in-principle deal with the Singapore-based Parkway group, the global leader in healthcare business, to spread its wings to Afro Asian countries. In the same year AHEL had launched a personal accident insurance card and commissioned the Italian Dental Clinic. The amalgamation of Indian Hospitals Corporation (IHCL), Om Sindoori Hotels (OSHL) with the company has been approved; also Deccan Hospital Corporation (DHCL) has been amalgamated with company. In 2001, the company signed a memorandum of understanding with the government of Mauritius, appointing the Apollo Hospitals Group as the preferred healthcare provider for all the citizens of Mauritius and in the identical year, made a tie-up with a local hospital initially to deliver mother and child care. During the year 2002, the hospital has taken over the 50.26 per cent of stake held by the Gauri Prasad Goenka in the Duncan Gleneagles Hospital for the consideration of Rs 3 crore. In 2003, AHEL made tie up with ICICI Lombard and unveiled an accident insurance product. Apollo launched a dedicated pediatric cardiac facility for children and sets up a 24X7 Chest Pain Clinic to offer round the clock and immediate access to quality heart care during the critical period. AHEL had entered into a major technology partnership with the Defence Research & Development Organisation (DRDO) to leverage mutual strengths during the period of 2004. Launched the Apollo National Heart Plan' comprising three components of the preventive mode, a disease management programme (DMP) and the actual treatment and surgery component. And also in the same year, it made a partnership to provide advisory services to Hayel Saeed Anam (HSA) group, Yemen. Apollo Hospital Delhi gets JCI certification for its quality of care in a safe environment in the year 2005. In the same year, it forged alliance with Histotem and joined hands with Johns Hopkins. AHEL singed the Joint Venture Agreement with Deutsche Krankenversicherung AG (DKV) for setting up the Health Insurance Business in October 11 of the year 2006. AHEL had signed an agreement with Cadila Pharmaceuticals Limited as a partner in Apollo Hospitals International Limited, Ahmedabad. Also in the year the hospital had acquired the Zavata. The week magazine rated the Apollo Hospitals as the Best Private Sector Hospital in India for the year 2006. As at June 15th 2007, AHEL launched Health City, the first of its kind in Asia, at Hyderabad, an integrated healthcare delivery facility, spread over 33 acres, to cover disease prevention, management, wellness and research. As at January 2008, the hospital has signed an agreement with Hindustan Construction Co (HCC), a real estate firm, to set up the medicity inside the upcoming hill station named Lavasa in Maharashtra. With an eye on foreign patients, Apollo Hospitals is setting up a medicity near Pune that will offer 'first rate ayurveda treatment'. The Apollo and BAI Medical Centre Ltd, a subsidiary of British American Investment Co (Mtius) Ltd Made a JV in February of the year 2008 to set up a hospital in Mauritius. Apollo Hospitals Enterprise Ltd (AHEL) and Quintiles Mauritius Holdings Inc., (Quintiles) entered into a Shareholders Agreement on 27 January 2009 for setting up a Phase I clinical trial research facility in Hyderabad at an estimated cost of USD 6 million, through a separate joint venture company to be formed for this purpose. Quintiles and AHEL will be funding the project cost in the ratio of 60-40 respectively through a combination of debt and/or equity. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 January 2010 approved the allotment of 1,500 Unsecured Foreign Currency Convertible Bonds (FCCB) of face value of USD 10,000 each aggregating to US$ 15 million with an option of convertible into equity shares at a price of Rs 605 per share to International Finance Corporation, Washington. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 May 2010 approved the sub-division of each existing equity share of nominal value of Rs 10 each into 2 equity shares of nominal value of Rs 5 each. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 9 December 2010 approved the allotment of 11.40 lakh equity shares to International Finance Corporation, Washington on conversion of Foreign Currency Convertible Bonds to the extent of US$ 7.50 million. These shares have been issued at a price of Rs 302.50 per share at a premium of 14% over the floor price determined as per the FCCB Scheme, 1993 (after the subdivision of each equity share of face value of Rs. 10/- per share into two equity shares of face value of Rs. 5/- each) and in accordance with the terms of the FCCB Loan Agreement dated 18 June 2009. On 18 July 2011, Apollo Hospitals Enterprise closed qualified institutional placement of equity shares. The company will issue 66.66 lakh equity shares at a price of Rs 495 per share to qualified institutional buyers for an amount aggregating Rs 330 crore. On 7 June 2012, Apollo Hospitals Enterprise announced that International Finance Corporation (IFC), Washington had sent a communication to the company requesting for conversion of the balance loan amount of USD 7.50 million of the Foreign Currency Convertible Bonds (FCCBs) into equity shares. In this regard, committee of the Board of Directors at its meeting held on 7 June 2012 approved the allotment of 13.81 lakh equity shares to International Finance Corporation, Washington. On 10 December 2012, Apollo Hospitals Enterprise announced that it has signed a definitive agreement with Sutherland Global Services, a global provider of business process and technology management services, to enable Sutherland Global Services acquire 100% of the shares of Apollo Health Street Limited (AHS), a leading provider of healthcare business services and world-class Health Information Technology (HIT) based solutions. AHS is an associate company of Apollo Hospitals Enterprise. This acquisition will position the combined organization as a leading healthcare service provider with comprehensive information technology and business process integrated solutions and consolidate its presence as a dominant player in the $38 billion US healthcare business process outsourcing (BPO). This also fosters Apollo Hospitals' strategic intent of focusing and growing its core healthcare delivery services. On 21 January 2013, Apollo Hospitals Enterprise announced its plans to establish a Proton Therapy Center in India, the first of its kind across South East Asia, Africa and Australia. This launch that marks the beginning of the next wave of advancement in radiation therapy in India is worth approximately Rs 400 crore, which covers the equipment and services supplied by IBA (Ion Beam Applications S.A.) to help establish the Apollo Proton Therapy Center including the long-term operation and maintenance contract. On 17 September 2014, Apollo Hospitals Enterprise announced that it has entered into an MoU with Hetero Med Solutions Limited (HMSL) for the acquisition of its retail pharmacy stores currently operated in Telengana, Andhra Pradesh and Tamilnadu. The acquisition would be in the form of purchase of the business undertaking, on a slump sale basis and comprises of 320 pharmacy stores, at an overall consideration not exceeding Rs 146 crore. This acquisition will further strengthen Apollo Pharmacy's leadership position in the industry. The addition of 320 stores are in existing core geographies where Apollo Pharmacy has a strong market presence and further consolidate its presence as a significant player in this region. Apollo Pharmacy plans to leverage its existing backend infrastructure to drive economies of scale, thereby accelerating profitability for these stores. This will also create an opportunity to increase the sales of Apollo private label products. Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced on 30 January 2014 that Sanofi-Synthelabo (India) Limited has invested into Apollo Sugar Clinics Limited (ASCL). ASCL is a disease management clinic focused on providing high quality, integrated care across its clinics for people with diabetes. An amount of Rs 90 crore is being invested by Sanofi-Synthelabo in this venture through a combination of primary and secondary funding. Earlier, on 30 September 2014, Apollo Hospitals Enterprise and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics. On 6 January 2015, Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced that it has successfully completed the acquisition of Nova Specialty Hospitals. The deal size would be in the range of Rs 135-145 crore. Nova Specialty Hospitals' existing centres will serve as new centres under the Apollo brand name. The acquired chain of Nova Specialty Hospitals is spread over 8 cities and will add to the Apollo network 45 Modular OTs, over 350 patient beds, with an average 20,000 SFT of built-up space in each centre. These centres provide both In-patient and OPD services with 60% of the procedures currently being done as day procedures. The Board of Directors of Apollo Energy Company Ltd., an Apollo Hospitals Group Company, at its meeting held on 25 January 2016 approved the divestment of 23.3% shareholding in Apollo Munich Health Insurance Company Ltd. (Apollo Munich) to its joint venture partner, Munich Re of Germany for Rs 163.5 crore. Post consummation of the transaction, Apollo Hospitals Group's shareholding in Apollo Munich shall stand reduced from 74.4% to 51.1%. Correspondingly, Munich Re's shareholding in Apollo Munich shall increase to 48.7% and 0.2% stake will be held by employees. Apollo Hospitals shall continue to hold its stake in Apollo Munich. Apollo Munich Health Insurance is one of the largest private sector health insurance companies offering comprehensive health insurance plans for individuals, families, senior citizens and corporates. On 12 March 2016, Apollo Hospitals Enterprise announced that it has completed the acquisition of 51% majority stake in Assam Hospitals Limited, Guwahati for a cash consideration of Rs 57.25 crore which will be utilized for refurbishing the hospital including addition of new equipments as well as towards expansion of the existing hospital block. Assam Hospitals Limited which was incorporated in 1997 and commenced operations from 1999, is engaged in the business of healthcare services. It has a presence in Guwahati where it currently runs a 220 bed hospital facility. The objective of the acquisition is to strengthen Apollo Hospitals leadership position in the hospital space as well as enhance its presence in North eastern region where it already has strong brand equity. On 20 June 2016, Apollo Hospitals Enterprise and Hainan Ecological Smart City Group (HESCG), China signed a Memorandum of Understanding (MoU) to build a state-of-the art hospital in Hainan Province, China. HESCG will provide land, all investments for the construction, commissioning and equipping the hospital besides all operative expenses, while Apollo Hospitals Group would provide its services technical consulting, planning and commissioning of the hospital and post completion of the hospital, provide services for the operations and management of the hospital. Apollo Hospitals would also support in building the technical and management personnel, install it's acclaimed patient care clinical protocols and practices. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 1 September 2016 discussed and deliberated the possibility of considering and evaluating various options to restructure and reorganize the businesses of the company, by re-aligning the business lines as per verticals. The proposal for such restructuring is aimed at exploring options for improving operational efficiencies and augmenting further growth of the businesses in compliances with the applicable laws and creating greater flexibility through such restructuring and/or transfer of the existing businesses into separate legal entities, given the large opportunity that exits in the healthcare sector. On 1 December 2016, Apollo Hospitals Enterprise announced that International Finance Corporation (affiliated to the World Bank) along with associated entity, has made a primary equity infusion of Rs 450 crore thereby acquiring a 29.03% stake in Apollo Health and Lifestyle Limited (AHLL), earlier a wholly owned subsidiary of the company. The equity infusion will be utilized to finance AHLL's growth plans. AHLL is engaged in retail healthcare business encompassing primary health clinics, birthing centres, dental & dialysis centres, day surgery centres and sugar clinics. During the FY2017, the company has allotted 2000 Non Convertible Debentures of face value of Rs 1 million each to HDFC Bank Limited, 2,500 Non Convertible Debenture of face value of Rs 1 million each to Yes Bank Limited and 500 Non Convertible Debenture of face value of Rs 1 million each to Birla Sun Life Insurance Company Limited. The Company had reduced its equity stake to 40% from 100% in Apollo Healthcare Technology Solutions Limited (AHTSL) on 23rd January 2017. However AHTSL shall continue to be a subsidiary of the Company due to the definition of controlling interest between the companies as per Ind AS standards. One multi-speciality hospital at Navi, Mumbai was inaugurated during the year 2016-17. As on 31st March 2017, your Company had eighteen direct subsidiaries, four step down subsidiaries, three joint ventures, and four associate companies. During the FY2017,Apollo Hospital International Limited and Future Parking Private Limited have become the subsidiaries of the company. During the year, Apollo Hospitals, Chennai and Indraprastha Apollo Hospitals, New Delhi were awarded the top 2 positions in the All India Critical Care Hospital Survey 2017 by Times Health. As on 31st March 2019, the Company had nineteen direct subsidiaries, ten step down subsidiaries, four joint ventures and four associate companies. The Board of Directors at their meeting held on November 14, 2018 have approved a Scheme of Arrangement ('the Scheme') between Apollo Hospitals Enterprise Limited ('AHEL') and Apollo Pharmacies Limited ('APL') and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business ('the disposal group') carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities. Pursuant to the Scheme of Arrangement (the Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT) vide order dated August 3, 2020, with effect from April 1, 2019 (Appointed date'), the front-end retail pharmacy included in the standalone pharmacy segmentis transferred to Apollo Pharmacies Limited ('APL'), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.52,780 lakhs. In accordance with Section 230 of the Companies Act, the Company filed the NCLT order with the Ministry of Company Affairs (Registrar of Companies) on September 1, 2020. Consequentto the filing, the Scheme became effective from September 1, 2020 (effective date'). The Company holds 25.5% of the equity shares in AMPL as on the effective date. The Board of Directors at their meeting held on February 13, 2020 had approved the amalgamation of Apollo Home Healthcare (India) Limited and Western Hospitals Corporation Private Limited, wholly owned subsidiaries of the Company ('Transferor Companies') into Apollo Hospitals Enterprise Limited (Transferee Company) by way of a Scheme of Amalgamation between the Transferor Companies and the Transferee Company and their respective shareholders and creditors, in accordance with Sections 230 to 234 of the Companies Act, 2013. The amalgamation is subject to requisite statutory and regulatory approvals and sanction by the respective shareholders of each of the companies involved in the scheme. There will not be any change in the shareholding pattern of the Transferee Company pursuant to implementation of the Scheme of Amalgamation as the Transferor Companies are wholly owned subsidiaries of the Transferee Company. During the FY2020, Apollo Healthcare Technology Solutions Limited, a subsidiary of the Company had applied for strike off of its name to the Registrar of Companies on 19th March 2020. The Company had divested its entire equity stake in Apollo Munich Health Insurance Company Ltd (AMHIL) on 9th January 2020 and consequently. AMHIL has ceased to be an Associate Company. As on 31st March 2020, Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 3 associate companies. As on 31 March 2020, AHEL had a network of 71 hospitals with total bed capacity of 10261. The Board of Directors, in their meeting held on November 11, 2020 have approved the proposal for executing a definitive Share Purchase Agreement (SPA) for the acquisition of 50% equity stake held by Gleneagles Development PTE Limited, Singapore, in Apollo Gleneagles Hospital Limited, Kolkata ('AGHL'), a joint venture in which the Company holds a 50% equity stake, for a cash consideration of Rs 41,000 lakhs. The Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 4 associate companies as on 31 March, 2021. The company completed a QIP in January 2021,allotting an additional 4659498 equity shares at a price of Rs 2511 per share (premium of Rs 2506 per share) aggregating to a sum of Rs 116999.99 lakhs. The Scheme of Arrangement relating to transfer of front end portion of retail pharmacy business (divestment business) to Apollo Pharmacies Limited (APL or Transferee Company) , a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs. 5,278 million was approved by the National Company Law Tribunal vide their order dated August 3, 2020. Pursuant to the Scheme becoming effective from 1st September, 2020, the Company invested a sum of Rs. 365 million towards its share of equity contribution and its ownership interest in AMPL reduced to 25.50% . On 07 January 2021, the company acquired 1% additional stake in Medics International Life Sciences Limited, a Joint Venture,which runs a 330-bedded hospital in Lucknow. Consequently Medics became the subsidiary of the Company. During year 2021, Company acquired the entire equity stake held by the existing shareholders in Apollo Health Co Limited (AHL) on 23rd June 2021. Consequent to that, AHL became a wholly owned subsidiary to the Company. The Company had received approval on June 28, 2021 for Scheme of Amalgamation with the wholly owned subsidiary companies, Apollo Home Healthcare (India) Limited (AHHCL) and Western Hospitals Corporation Private Limited (WHCPL). The Appointed Date for the Scheme was 1st April, 2020 and the entire assets and liabilities of AHHCL and WHCPL got transferred to and recorded by Company. The entire share capital of AHHCL and WHCPL held by Company, stood cancelled without any further act or deed and no consideration was issued upon the amalgamation coming into effect. As on 31st March 2022, the Company had 18 direct subsidiaries, 12 step down subsidiaries, 2 joint ventures and 3 associate companies. The Board of Directors, in their meeting held on November 11, 2020 acquired 50% equity stake held by Gleneagles Development Pte Ltd., Singapore in AMSHL, in which the Company held a 50% equity stake at a consideration of Rs. 4,100 million. The Company acquired 50% equity stake held in AMSHL by Gleneagles Development Pte Limited on 22nd April, 2021. Consequently, AMSHL became a wholly-owned subsidiary of the Company effective from April 22, 2021, and name of the Company was changed from Apollo Gleneagles Hospital Limited to Apollo Multispeciality Hospitals Limited based on the approval obtained from the Ministry of Corporate Affairs on 5th May, 2021. Effective 16th March 2022, the Pharmacy Distribution business along with the Omni channel digital healthcare platform Apollo 24/7 and the Company's equity interest in Apollo Medical Private Limited was transferred to Apollo HealthCo Limited which is a wholly owned subsidiary of AHEL, through a slump sale process for a net consideration of Rs. 12,100 million. As of March 31, 2022 the Company had a capacity of 9,911 beds in 71 hospitals located in India and overseas. Of the 9,911 beds, 8,538 beds are located in 44 owned hospitals, 278 beds in 11 cradles, 244 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals under their management through operations and management contracts. During 2022-23, the Company acquired a 60% equity stake in Kerala First Health Services Private Limited (KFHSL), for a consideration costing Rs 26.4 Crores and consequently, KFHSL became a subsidiary of the Company. As of March 31, 2023, Company had a capacity of 9,957 beds in 70 hospitals located in India and overseas. Of the 9,957 beds, 8,544 beds are located in 43 owned hospitals, 305 beds in 11 cradles, 257 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals operated through operations and management contracts. The Apollo Proton Cancer Center was opened in Chennai in FY'23.

Apollo Hospitals Enterprise Ltd Chairman Speech

For 40 years, Apollo has been steadfast in providing world-class integrated healthcare to patients with outcomes which are comparable to the best healthcare institutions in the world and is now ready to deliver the healthcare needs of the future. What does the future of healthcare hold for us – for you, the consumer, and us, the care provider? The future of healthcare is going to led largely by consumers and driven by technology like Artificial Intelligence and digitalization. Robotics and 3D printing are revolutionizing the way healthcare is being delivered.

We have always put our patient on the fulcrum of our business and focused on building a health delivery system that brings together doctors with exemplary skills and experience in state-of-the-art facilities underscored by clinical and service excellence. Over these long years we have been consistent in bringing the latest medical equipment to India, investing in cutting-edge technologies, and staying abreast of the breakthroughs in medical treatment. All because we want to delight our patient with a differentiated care experience. This is the reason that our outcomes match or better those at leading hospitals worldwide; that we are the most extensive telemedicine consultants in India; that we are deploying AI and ML for predicting health risks; that Apollo 24/7, our digital healthcare services platform, provides medicine delivery, consultations, and diagnostics on the go. This in short, is what some may say is the future of healthcare; but we are already well heeled into the various aspects of that future.

There is a palpable tectonic shift in the exponential pace of digital adoption and futuristic innovation in the healthcare sector. The Digital India initiative by the Government of India is a farsighted measure which will usher in a new paradigm of socio-economic progress in the country. There will be sharp focus on agility, innovation, digital transformation, financial and environmental sustainability, and empowered talent with which to create enduring value for all stakeholders.

Apollo 24/7–India's Largest Healthcare Services Omnichannel

We have combined our legacy of clinical excellence with emerging technology to make superior healthcare easily available to every Indian online through Apollo 24/7. Patients can get a doctor consultation in 15 minutes or less from the comfort of their homes via video conferencing. They can schedule home pick-ups of samples for diagnostics with same-day report facility, and have their medicines delivered to their doorstep. The platform provides a real time connect with all Apollo formats and pan Apollo care continuum. Apollo 24/7 balances our physical brick and mortar pharmacies.

Apollo 24/7 has proved to be a beacon of hope for patients who were home bound or restricted in their movements due to the impact of COVID-19.

ProHealth–A Holistic Health Program

We continue to focus on wellness. Preventive Health is the proactive management of one's health and wellness. Over the last several decades, Non Communicable Diseases or NCDs have increased alarmingly as a result of lifestyle habits. Common among these are diabetes, hypertension, cardiovascular and respiratory conditions, and obesity. Even some cancers. However, many of these can be controlled through a reduction of modifiable risk factors. Our ProHealth program does exactly that. It is a first its kind health check which provides an AI based predictive risk score for NCDs. It creates awareness about lifestyle changes that can reduce the risk of the disease itself or arrest its progression. It empowers the patient to make informed health decisions. ProHealth is a one-time health record for an individual and provides pointers for preventing and mitigating the effects of any disease or sickness.

Use of Artificial Intelligence (AI) & Machine Learning (ML)

We are using AI and ML in clinical areas as well. We have developed extensive algorithms to help our doctors make point of care decisions to address clinical complexities. Importantly, it has helped us frame better quality clinical pathways for producing better outcomes.

Managing the Pandemic

We had a comprehensive, integrated COVID-19 management programme, across our network to fight the pandemic. In living our Patient First philosophy, we ensured patients had 24/7 access to quality healthcare — our ambulances and diagnostic services, Emergency Care, and both online and offline pharmacies across the country. We offered special procedures at home like blood transfusion, chemotherapy, virtual consultations, oxygen cylinder, and oxygen concentrator. India's COVID vaccination plan was ambitious with the target to immunize 1.3 billion population. The vaccination drive in India was flagged off on 16th January 2021 with the priority given to an estimated three crore health care and frontline workers.

Giving a Ray of Hope to People Around the World

As cancer care has become one of the fastest growing healthcare imperatives across the globe, the Apollo Proton Cancer Centre in Chennai, stands as a ray of hope for millions of cancer patients from 147 countries to access the most advanced cancer care. It gives them the courage to stand and stare cancer down. Proton therapy is a radiation therapy that uses tiny particles called protons. Because of the way protons deliver their energy, proton therapy does not damage as much healthy tissue as much as photon therapy. Therefore, a higher dose of radiation can be targeted at the tumor without affecting many normal healthy cells.

Minimally Invasive Surgeries

The Apollo Institute of Robotic Surgery has exceptional outcomes and is considered to be the best program for robotic surgery in India. We have 17 Robots across 11 facilities that perform minimally invasive surgeries with a shorter recovery time and lower blood loss. We have performed 1300+ Robotic Surgeries in FY22.

Enhancing Access to Quality Healthcare

We have India's most extensive TeleHealth Services network and are pioneers in that field. By leveraging the best available technology, we have been successful in enhancing access to quality healthcare for people in 16 States in India, especially for the under-served, last mile rural population.

Bringing Care Closer to Home– Apollo Health and Lifestyle

With over 1734 specialty neighborhood clinics which guarantee the signature Apollo quality of care and clinical excellence, we have brought healthcare to people's doorsteps. In combination with the other formats of care we offer, consumers can be in control of their health and wellness.

Continuum of Care

We offer home care, both short and long term, as an extension of our care continuum. We make no compromise in the quality of care or service we provide. This was very beneficial to patients during COVID times, especially for those undergoing rehab.

Medical Value Travel

Over the years our healthcare units have been recognized for their excellence in Medical Value Travel (MVT). India has medical expertise and potential that is on par with standards in developed countries. At Apollo Hospitals, we have always endeavored to provide world-class care with cutting edge technology to patients, but at a tenth of the cost of the same abroad. This has allowed us to extend the best quality of healthcare to people across the globe.

Healthcare continues to support the health of the country and its economy. We have the potential to soon become the Medical Tourism capital of the world. The Prime Minister, while appreciating Apollo Hospitals' efforts in the healthcare space and in driving MVT, also suggested that we adapt our ancient naturopathy practices with our modern healthcare practices and make ‘Heal in India' a bigger brand. MVT is a US$600 billion industry and we can get substantial value from this.

The Apollo Network Effect

We are always there for you. The power of the Apollo network ensures that there is a health facility close to you, no matter where you are. Beyond the brick and mortar, the power of the Apollo network extends through our highly skilled and experienced clinical fraternity, the group of doctors at Apollo, who are leaders in their field and offer caring service. The amalgamation of class-leading doctors with our cutting-edge technologies ensures that any doctor within our system is available to any patient in any part of the country at their doorstep, or in their palm of their hand.

We leave no stone unturned in finding a treatment to suit our patient's needs. For example, a 3-year-old child was successfully operated on for treating Wilms' Tumor; a 4-day old new-born baby, weighing 1.6 kg, successfully underwent Total Anomalous Pulmonary Venous Connection repair. Our doctors do not give up without a fight.

All our initiatives have resulted in strong financial results that i am happy to share with you. Patient footfalls have overtaken pre-COVID numbers and elective treatments are again on the rise. Our revenue stands at Rs 146,626 mio. Healthcare services has contributed 55% to our topline, and HealthCo 36%. Overall, the EBITDA (post ind as 116) stood at Rs 21,851 mio. I am delighted to announce a dividend of Rs 11.75 per share.

I would like to thank the board members for their unwavering trust and support in our journey into that future. I thank you, our esteemed shareholders for the tremendous trust you have reposed in us, without which support we will not be able to venture into new domains in healthcare delivery. Beyond anything, my gratitude goes to my Apollo family who have stood together with us on our journey. Without their unconditional support, we would have scored far fewer wins.

We understand that the future of healthcare will see the evolution of different formats of care and will continue to take us closer to the consumer. We are agile to seize the possibilities. It has been a very challenging period for healthcare over the last four decades. However, the Apollo Family has given the best healthcare outcomes and treated not only 100 million patients thus far but has been adept in being ready to meet future healthcare delivery needs, adopting cutting-edge technology across all our delivery formats. We will grow organically and inorganically to serve the needs of our people by leveraging the best in clinical care and healthcare technologies.

Let me remind you yet again, to take good care of yourselves. Your life is Priceless. Stay safe. Stay Healthy.

My warm personal regards to all of you,
Dr. Prathap C. Reddy
Executive Chairman, Apollo Hospitals Group
Dr. Prathap C Reddy
Founder and Executive_Chairman

   

Apollo Hospitals Enterprise Ltd Company History

Apollo Hospitals Enterprise Limited (AHEL) is a leading private sector healthcare provider in Asia. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics. AHEL's Hospitals are situated in Chennai, Hyderabad, Delhi, Ahmedabad, Pune, Chenganur, Coimbatore, Jaipur, Madurai, Anantpur, Nellore, Kurnool, Bhopal, Ranchi, Bilaspur and Bacheli. Apollo Hospitals Enterprise Limited was incorporated as a Public Limited Company on December 5, 1979, a comprehensive 250-bed hospital with an emphasis on speciality and super specialties in over fifty departments at Chennai. Dr. Prathap C Reddy promoted it. 46 beds were added in the year 1985. It is the first group of hospitals that pioneered the concept of corporate healthcare delivery in India. The Apollo Health Association (AHA) was inaugurated in April of the year 1986, based on credit card system. As per this scheme, the Apollo health insurance policyholders get Medicare offered by Apollo and 76 accredited hospitals in selected cities. The hospital was equipped with Magnetic Resonance Imaging (MRI) during the year 1989, also with SOMATOMCR whole body computed Tomography scanner, Dideoendoscopy and Mammography, breast-scanning equipment for the detection of occult carcinoma. During the same year 1989, AHEL group had finalised a joint venture project with the I.R.T.C. of Eye Micro Surgery, USSR to launch the Apollo Fyodorov Eye Research Institute. Apart from the hospital activities, The Apollo School of nursing was commissioned in August of the year1991, which offers a 3-year diploma programme followed by internship in the hospital. During the year 1992, 16 intensive care beds and 26 additional patient beds together with balancing equipment were added in various disciplines. Also a 24-hour ambulance service with wireless facility was to be launched. Apollo cancer hospital was commissioned with 150-beds for cancer treatment and research centre in Chennai during the period of 1993. Further, AHEL had introduced state-of-the-art Bone Marrow transplant facility in Phase II expansion of cancer project. A third theater was added for cardio thoracic surgery in the year of 1994. As at 19th February of the year 1995, another one wing was added, Cancer hospital in Hyderabad was inaugurated. In the same year 1995, AHEL had joined hands with the WHO with its mission to eradicate Tuberculosis in India. With takeover of Orient Hospital, Madurai and Pinakini Hospital, Nellore, the Company had added 300 more beds in the year 1996 and the Apollo College of Nursing at Keezhkattalai was inaugurated on 21st October of the same year. AHEL had signed a memorandum of understanding with Jardine of UK for successful adaptation of the health maintenance organisations (HMO) in the year 1997, a concept for the first time in India. A year after, in 1998, also signed a memorandum of understanding with the Sri Lankan Government to build a super-speciality hospital in Colombo. It was the first time the speciality hospital group ventured abroad with investments. AHEL had opened a unit for the Kidney disorders; it was inaugurated in April of the year 1998 with the expansion in this facility for better and newer techniques in treatment. In 1999, Apollo had launched its first poison information centre in the south of the India. Indian Oil Corporation Ltd (IOCL) and AHEL had signed a memorandum of understanding (MoU) in the year 2000 for setting up pharmaceutical general stores at the convenience stores of Indian Oil petrol stations. Apollo and Royal College of General Practioners made a tie-up in the period of 2000 to launch three programmes for revalidating and updating the knowledge of primary healthcare physicians in India. The company also inked an in-principle deal with the Singapore-based Parkway group, the global leader in healthcare business, to spread its wings to Afro Asian countries. In the same year AHEL had launched a personal accident insurance card and commissioned the Italian Dental Clinic. The amalgamation of Indian Hospitals Corporation (IHCL), Om Sindoori Hotels (OSHL) with the company has been approved; also Deccan Hospital Corporation (DHCL) has been amalgamated with company. In 2001, the company signed a memorandum of understanding with the government of Mauritius, appointing the Apollo Hospitals Group as the preferred healthcare provider for all the citizens of Mauritius and in the identical year, made a tie-up with a local hospital initially to deliver mother and child care. During the year 2002, the hospital has taken over the 50.26 per cent of stake held by the Gauri Prasad Goenka in the Duncan Gleneagles Hospital for the consideration of Rs 3 crore. In 2003, AHEL made tie up with ICICI Lombard and unveiled an accident insurance product. Apollo launched a dedicated pediatric cardiac facility for children and sets up a 24X7 Chest Pain Clinic to offer round the clock and immediate access to quality heart care during the critical period. AHEL had entered into a major technology partnership with the Defence Research & Development Organisation (DRDO) to leverage mutual strengths during the period of 2004. Launched the Apollo National Heart Plan' comprising three components of the preventive mode, a disease management programme (DMP) and the actual treatment and surgery component. And also in the same year, it made a partnership to provide advisory services to Hayel Saeed Anam (HSA) group, Yemen. Apollo Hospital Delhi gets JCI certification for its quality of care in a safe environment in the year 2005. In the same year, it forged alliance with Histotem and joined hands with Johns Hopkins. AHEL singed the Joint Venture Agreement with Deutsche Krankenversicherung AG (DKV) for setting up the Health Insurance Business in October 11 of the year 2006. AHEL had signed an agreement with Cadila Pharmaceuticals Limited as a partner in Apollo Hospitals International Limited, Ahmedabad. Also in the year the hospital had acquired the Zavata. The week magazine rated the Apollo Hospitals as the Best Private Sector Hospital in India for the year 2006. As at June 15th 2007, AHEL launched Health City, the first of its kind in Asia, at Hyderabad, an integrated healthcare delivery facility, spread over 33 acres, to cover disease prevention, management, wellness and research. As at January 2008, the hospital has signed an agreement with Hindustan Construction Co (HCC), a real estate firm, to set up the medicity inside the upcoming hill station named Lavasa in Maharashtra. With an eye on foreign patients, Apollo Hospitals is setting up a medicity near Pune that will offer 'first rate ayurveda treatment'. The Apollo and BAI Medical Centre Ltd, a subsidiary of British American Investment Co (Mtius) Ltd Made a JV in February of the year 2008 to set up a hospital in Mauritius. Apollo Hospitals Enterprise Ltd (AHEL) and Quintiles Mauritius Holdings Inc., (Quintiles) entered into a Shareholders Agreement on 27 January 2009 for setting up a Phase I clinical trial research facility in Hyderabad at an estimated cost of USD 6 million, through a separate joint venture company to be formed for this purpose. Quintiles and AHEL will be funding the project cost in the ratio of 60-40 respectively through a combination of debt and/or equity. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 January 2010 approved the allotment of 1,500 Unsecured Foreign Currency Convertible Bonds (FCCB) of face value of USD 10,000 each aggregating to US$ 15 million with an option of convertible into equity shares at a price of Rs 605 per share to International Finance Corporation, Washington. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 May 2010 approved the sub-division of each existing equity share of nominal value of Rs 10 each into 2 equity shares of nominal value of Rs 5 each. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 9 December 2010 approved the allotment of 11.40 lakh equity shares to International Finance Corporation, Washington on conversion of Foreign Currency Convertible Bonds to the extent of US$ 7.50 million. These shares have been issued at a price of Rs 302.50 per share at a premium of 14% over the floor price determined as per the FCCB Scheme, 1993 (after the subdivision of each equity share of face value of Rs. 10/- per share into two equity shares of face value of Rs. 5/- each) and in accordance with the terms of the FCCB Loan Agreement dated 18 June 2009. On 18 July 2011, Apollo Hospitals Enterprise closed qualified institutional placement of equity shares. The company will issue 66.66 lakh equity shares at a price of Rs 495 per share to qualified institutional buyers for an amount aggregating Rs 330 crore. On 7 June 2012, Apollo Hospitals Enterprise announced that International Finance Corporation (IFC), Washington had sent a communication to the company requesting for conversion of the balance loan amount of USD 7.50 million of the Foreign Currency Convertible Bonds (FCCBs) into equity shares. In this regard, committee of the Board of Directors at its meeting held on 7 June 2012 approved the allotment of 13.81 lakh equity shares to International Finance Corporation, Washington. On 10 December 2012, Apollo Hospitals Enterprise announced that it has signed a definitive agreement with Sutherland Global Services, a global provider of business process and technology management services, to enable Sutherland Global Services acquire 100% of the shares of Apollo Health Street Limited (AHS), a leading provider of healthcare business services and world-class Health Information Technology (HIT) based solutions. AHS is an associate company of Apollo Hospitals Enterprise. This acquisition will position the combined organization as a leading healthcare service provider with comprehensive information technology and business process integrated solutions and consolidate its presence as a dominant player in the $38 billion US healthcare business process outsourcing (BPO). This also fosters Apollo Hospitals' strategic intent of focusing and growing its core healthcare delivery services. On 21 January 2013, Apollo Hospitals Enterprise announced its plans to establish a Proton Therapy Center in India, the first of its kind across South East Asia, Africa and Australia. This launch that marks the beginning of the next wave of advancement in radiation therapy in India is worth approximately Rs 400 crore, which covers the equipment and services supplied by IBA (Ion Beam Applications S.A.) to help establish the Apollo Proton Therapy Center including the long-term operation and maintenance contract. On 17 September 2014, Apollo Hospitals Enterprise announced that it has entered into an MoU with Hetero Med Solutions Limited (HMSL) for the acquisition of its retail pharmacy stores currently operated in Telengana, Andhra Pradesh and Tamilnadu. The acquisition would be in the form of purchase of the business undertaking, on a slump sale basis and comprises of 320 pharmacy stores, at an overall consideration not exceeding Rs 146 crore. This acquisition will further strengthen Apollo Pharmacy's leadership position in the industry. The addition of 320 stores are in existing core geographies where Apollo Pharmacy has a strong market presence and further consolidate its presence as a significant player in this region. Apollo Pharmacy plans to leverage its existing backend infrastructure to drive economies of scale, thereby accelerating profitability for these stores. This will also create an opportunity to increase the sales of Apollo private label products. Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced on 30 January 2014 that Sanofi-Synthelabo (India) Limited has invested into Apollo Sugar Clinics Limited (ASCL). ASCL is a disease management clinic focused on providing high quality, integrated care across its clinics for people with diabetes. An amount of Rs 90 crore is being invested by Sanofi-Synthelabo in this venture through a combination of primary and secondary funding. Earlier, on 30 September 2014, Apollo Hospitals Enterprise and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics. On 6 January 2015, Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced that it has successfully completed the acquisition of Nova Specialty Hospitals. The deal size would be in the range of Rs 135-145 crore. Nova Specialty Hospitals' existing centres will serve as new centres under the Apollo brand name. The acquired chain of Nova Specialty Hospitals is spread over 8 cities and will add to the Apollo network 45 Modular OTs, over 350 patient beds, with an average 20,000 SFT of built-up space in each centre. These centres provide both In-patient and OPD services with 60% of the procedures currently being done as day procedures. The Board of Directors of Apollo Energy Company Ltd., an Apollo Hospitals Group Company, at its meeting held on 25 January 2016 approved the divestment of 23.3% shareholding in Apollo Munich Health Insurance Company Ltd. (Apollo Munich) to its joint venture partner, Munich Re of Germany for Rs 163.5 crore. Post consummation of the transaction, Apollo Hospitals Group's shareholding in Apollo Munich shall stand reduced from 74.4% to 51.1%. Correspondingly, Munich Re's shareholding in Apollo Munich shall increase to 48.7% and 0.2% stake will be held by employees. Apollo Hospitals shall continue to hold its stake in Apollo Munich. Apollo Munich Health Insurance is one of the largest private sector health insurance companies offering comprehensive health insurance plans for individuals, families, senior citizens and corporates. On 12 March 2016, Apollo Hospitals Enterprise announced that it has completed the acquisition of 51% majority stake in Assam Hospitals Limited, Guwahati for a cash consideration of Rs 57.25 crore which will be utilized for refurbishing the hospital including addition of new equipments as well as towards expansion of the existing hospital block. Assam Hospitals Limited which was incorporated in 1997 and commenced operations from 1999, is engaged in the business of healthcare services. It has a presence in Guwahati where it currently runs a 220 bed hospital facility. The objective of the acquisition is to strengthen Apollo Hospitals leadership position in the hospital space as well as enhance its presence in North eastern region where it already has strong brand equity. On 20 June 2016, Apollo Hospitals Enterprise and Hainan Ecological Smart City Group (HESCG), China signed a Memorandum of Understanding (MoU) to build a state-of-the art hospital in Hainan Province, China. HESCG will provide land, all investments for the construction, commissioning and equipping the hospital besides all operative expenses, while Apollo Hospitals Group would provide its services technical consulting, planning and commissioning of the hospital and post completion of the hospital, provide services for the operations and management of the hospital. Apollo Hospitals would also support in building the technical and management personnel, install it's acclaimed patient care clinical protocols and practices. The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 1 September 2016 discussed and deliberated the possibility of considering and evaluating various options to restructure and reorganize the businesses of the company, by re-aligning the business lines as per verticals. The proposal for such restructuring is aimed at exploring options for improving operational efficiencies and augmenting further growth of the businesses in compliances with the applicable laws and creating greater flexibility through such restructuring and/or transfer of the existing businesses into separate legal entities, given the large opportunity that exits in the healthcare sector. On 1 December 2016, Apollo Hospitals Enterprise announced that International Finance Corporation (affiliated to the World Bank) along with associated entity, has made a primary equity infusion of Rs 450 crore thereby acquiring a 29.03% stake in Apollo Health and Lifestyle Limited (AHLL), earlier a wholly owned subsidiary of the company. The equity infusion will be utilized to finance AHLL's growth plans. AHLL is engaged in retail healthcare business encompassing primary health clinics, birthing centres, dental & dialysis centres, day surgery centres and sugar clinics. During the FY2017, the company has allotted 2000 Non Convertible Debentures of face value of Rs 1 million each to HDFC Bank Limited, 2,500 Non Convertible Debenture of face value of Rs 1 million each to Yes Bank Limited and 500 Non Convertible Debenture of face value of Rs 1 million each to Birla Sun Life Insurance Company Limited. The Company had reduced its equity stake to 40% from 100% in Apollo Healthcare Technology Solutions Limited (AHTSL) on 23rd January 2017. However AHTSL shall continue to be a subsidiary of the Company due to the definition of controlling interest between the companies as per Ind AS standards. One multi-speciality hospital at Navi, Mumbai was inaugurated during the year 2016-17. As on 31st March 2017, your Company had eighteen direct subsidiaries, four step down subsidiaries, three joint ventures, and four associate companies. During the FY2017,Apollo Hospital International Limited and Future Parking Private Limited have become the subsidiaries of the company. During the year, Apollo Hospitals, Chennai and Indraprastha Apollo Hospitals, New Delhi were awarded the top 2 positions in the All India Critical Care Hospital Survey 2017 by Times Health. As on 31st March 2019, the Company had nineteen direct subsidiaries, ten step down subsidiaries, four joint ventures and four associate companies. The Board of Directors at their meeting held on November 14, 2018 have approved a Scheme of Arrangement ('the Scheme') between Apollo Hospitals Enterprise Limited ('AHEL') and Apollo Pharmacies Limited ('APL') and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business ('the disposal group') carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities. Pursuant to the Scheme of Arrangement (the Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT) vide order dated August 3, 2020, with effect from April 1, 2019 (Appointed date'), the front-end retail pharmacy included in the standalone pharmacy segmentis transferred to Apollo Pharmacies Limited ('APL'), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.52,780 lakhs. In accordance with Section 230 of the Companies Act, the Company filed the NCLT order with the Ministry of Company Affairs (Registrar of Companies) on September 1, 2020. Consequentto the filing, the Scheme became effective from September 1, 2020 (effective date'). The Company holds 25.5% of the equity shares in AMPL as on the effective date. The Board of Directors at their meeting held on February 13, 2020 had approved the amalgamation of Apollo Home Healthcare (India) Limited and Western Hospitals Corporation Private Limited, wholly owned subsidiaries of the Company ('Transferor Companies') into Apollo Hospitals Enterprise Limited (Transferee Company) by way of a Scheme of Amalgamation between the Transferor Companies and the Transferee Company and their respective shareholders and creditors, in accordance with Sections 230 to 234 of the Companies Act, 2013. The amalgamation is subject to requisite statutory and regulatory approvals and sanction by the respective shareholders of each of the companies involved in the scheme. There will not be any change in the shareholding pattern of the Transferee Company pursuant to implementation of the Scheme of Amalgamation as the Transferor Companies are wholly owned subsidiaries of the Transferee Company. During the FY2020, Apollo Healthcare Technology Solutions Limited, a subsidiary of the Company had applied for strike off of its name to the Registrar of Companies on 19th March 2020. The Company had divested its entire equity stake in Apollo Munich Health Insurance Company Ltd (AMHIL) on 9th January 2020 and consequently. AMHIL has ceased to be an Associate Company. As on 31st March 2020, Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 3 associate companies. As on 31 March 2020, AHEL had a network of 71 hospitals with total bed capacity of 10261. The Board of Directors, in their meeting held on November 11, 2020 have approved the proposal for executing a definitive Share Purchase Agreement (SPA) for the acquisition of 50% equity stake held by Gleneagles Development PTE Limited, Singapore, in Apollo Gleneagles Hospital Limited, Kolkata ('AGHL'), a joint venture in which the Company holds a 50% equity stake, for a cash consideration of Rs 41,000 lakhs. The Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 4 associate companies as on 31 March, 2021. The company completed a QIP in January 2021,allotting an additional 4659498 equity shares at a price of Rs 2511 per share (premium of Rs 2506 per share) aggregating to a sum of Rs 116999.99 lakhs. The Scheme of Arrangement relating to transfer of front end portion of retail pharmacy business (divestment business) to Apollo Pharmacies Limited (APL or Transferee Company) , a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs. 5,278 million was approved by the National Company Law Tribunal vide their order dated August 3, 2020. Pursuant to the Scheme becoming effective from 1st September, 2020, the Company invested a sum of Rs. 365 million towards its share of equity contribution and its ownership interest in AMPL reduced to 25.50% . On 07 January 2021, the company acquired 1% additional stake in Medics International Life Sciences Limited, a Joint Venture,which runs a 330-bedded hospital in Lucknow. Consequently Medics became the subsidiary of the Company. During year 2021, Company acquired the entire equity stake held by the existing shareholders in Apollo Health Co Limited (AHL) on 23rd June 2021. Consequent to that, AHL became a wholly owned subsidiary to the Company. The Company had received approval on June 28, 2021 for Scheme of Amalgamation with the wholly owned subsidiary companies, Apollo Home Healthcare (India) Limited (AHHCL) and Western Hospitals Corporation Private Limited (WHCPL). The Appointed Date for the Scheme was 1st April, 2020 and the entire assets and liabilities of AHHCL and WHCPL got transferred to and recorded by Company. The entire share capital of AHHCL and WHCPL held by Company, stood cancelled without any further act or deed and no consideration was issued upon the amalgamation coming into effect. As on 31st March 2022, the Company had 18 direct subsidiaries, 12 step down subsidiaries, 2 joint ventures and 3 associate companies. The Board of Directors, in their meeting held on November 11, 2020 acquired 50% equity stake held by Gleneagles Development Pte Ltd., Singapore in AMSHL, in which the Company held a 50% equity stake at a consideration of Rs. 4,100 million. The Company acquired 50% equity stake held in AMSHL by Gleneagles Development Pte Limited on 22nd April, 2021. Consequently, AMSHL became a wholly-owned subsidiary of the Company effective from April 22, 2021, and name of the Company was changed from Apollo Gleneagles Hospital Limited to Apollo Multispeciality Hospitals Limited based on the approval obtained from the Ministry of Corporate Affairs on 5th May, 2021. Effective 16th March 2022, the Pharmacy Distribution business along with the Omni channel digital healthcare platform Apollo 24/7 and the Company's equity interest in Apollo Medical Private Limited was transferred to Apollo HealthCo Limited which is a wholly owned subsidiary of AHEL, through a slump sale process for a net consideration of Rs. 12,100 million. As of March 31, 2022 the Company had a capacity of 9,911 beds in 71 hospitals located in India and overseas. Of the 9,911 beds, 8,538 beds are located in 44 owned hospitals, 278 beds in 11 cradles, 244 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals under their management through operations and management contracts. During 2022-23, the Company acquired a 60% equity stake in Kerala First Health Services Private Limited (KFHSL), for a consideration costing Rs 26.4 Crores and consequently, KFHSL became a subsidiary of the Company. As of March 31, 2023, Company had a capacity of 9,957 beds in 70 hospitals located in India and overseas. Of the 9,957 beds, 8,544 beds are located in 43 owned hospitals, 305 beds in 11 cradles, 257 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals operated through operations and management contracts. The Apollo Proton Cancer Center was opened in Chennai in FY'23.

Apollo Hospitals Enterprise Ltd Directors Reports

Apollo Hospitals Enterprise Ltd Company Background

Shobana KamineniSuneeta Reddy
Incorporation Year1979
Registered OfficeNo 19 Bishop Garden,Raja Annamalaipuram
Chennai,Tamil Nadu-600028
Telephone91-44-28290956/28293896,Managing Director
Fax91-44-28290956
Company SecretaryS M Krishnan
AuditorDeloitte Haskins & Sells LLP
Face Value5
Market Lot1
ListingBSE,Luxembourg,MSEI ,NASDAQ,NSE,
RegistrarIntegrated Registry Mgt Servic
Kences Tower ,2nd Floor No 1 ,Ramakrishna Street ,Chennai - 600 017

Apollo Hospitals Enterprise Ltd Company Management

Director NameDirector DesignationYear
Prathap C ReddyExecutive Chairman2023
Preetha ReddyExecutive Vice Chairperson2023
Suneeta ReddyManaging Director2023
Sangita ReddyJoint Managing Director2023
Shobana KamineniExecutive Vice Chairperson2023
S M KrishnanSenior Vice President & CS2023
Vinayak ChatterjeeIndependent Director2023
Murali DoraiswamyIndependent Director2023
V Kavitha DuttIndependent Director2023
M B N RaoLead Independent Director2023
Som MittalIndependent Director2023
Rama BijapurkarIndependent Director2023

Apollo Hospitals Enterprise Ltd Listing Information

Listing Information
NIFTY
BSE_500
BSE_HC
BSE_100
BSE_200
BSEDOLLEX
CNX500
CNX100
CNXINFRAST
CNXSERVICE
CNXCONSUMP
CNX200
BSEGREENEX
BSECARBONE
NFT100LQ15
NFT100EQWT
BSEALLCAP
BSELARGECA
SENSEX50
LMI250
BSEDSI
NFT50EQWT
BSE100LTMC
NFTYLM250
NFTY100ESG
NFTYHEALTH
NF500M5025
NFTYTOTMKT
NMIF503020

Apollo Hospitals Enterprise Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Health care ServicesRs.0004900.2
Revenue from Sale at PharmacieRs.0004820.6
Project Consultancy IncomeRs.00066.1
Clinical Trial ServicesRs.0005.7
Franchise FeesRs.0001.9
Other Operating IncomeNA0000

Contact us Contact us